Company: RCUS
Filing Date: 2025-10-31
Form Type: 424B5
Source: 0001193125-25-260836
Chunk: 26

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-31
Form: 424B5
Chunk 26
---
60 days after the date of this prospectus supplement, except with the prior written consent of the representatives.
These restrictions do not apply to:

(i) the issuance of shares in this offering;

(ii) the issuance of common stock or any securities convertible into, or exercisable for, shares of common stock pursuant to our equity incentive plans and
employee stock purchase plan and such other plans and arrangements as are in existence on the date of this prospectus supplement;

(iii) the issuance of
common stock pursuant to the valid exercises, vesting or settlements of options, other equity awards, warrants or rights outstanding on the date of this prospectus supplement;

(iv) the filing of a registration statement on Form S-8 in connection with the registration of common stock issuable
under any employee benefit plan adopted and approved by the company’s board of directors;

(v) the issuance of up to 7.5% of the outstanding shares
of our common stock or securities convertible into or exercisable or exchangeable for shares of our common stock pursuant to a strategic partnership, joint venture, merger, collaboration, lending or other contractual arrangement, or in connection
with the acquisition or license by us of any business, products or technologies, provided that such recipients enter into a lock-up agreement with the underwriters; and

(vi) the issuance and sale of common stock pursuant to that certain Equity Distribution Agreement, dated February 28, 2023, by and among us, Goldman
Sachs & Co. LLC and Leerink Partners LLC, provided that no sales shall be made under such agreement until 30 calendar days after the date of this prospectus supplement.

In addition, our officers, directors, and a certain stockholder have also agreed with the underwriters, subject to certain exceptions, not to directly or
indirectly offer for sale, sell, pledge, enter into any swap or other derivatives transaction that transfers any of the economic benefits or risks of ownership of our common stock, or otherwise dispose of any shares of our common stock or any
securities that may be converted into or exchanged for any shares of our common stock during the period from the date of this prospectus supplement continuing through the date 60 days after the date of this prospectus supplement, except with the
prior written consent of the representatives. These restrictions do not apply, subject in certain cases to various conditions, to certain transactions, including:

(i) transfers of a bona fide gift or gifts, charitable contributions or for bona fide estate planning purposes;

(ii) transfers upon